Bicara Therapeutics Inc.

BCAX

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$18.00 17,500,000 Positive High 29%

Offering Team

Deal Managers

  • Morgan Stanley
  • Cowen and Company
  • Cantor Fitzgerald

Lawyers

  • Goodwin Procter LLP

Auditors

  • KPMG LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Through this dual-targeting mechanism, ficerafusp alfa has the potential to exe More

Deal Tracker

Investors

Filing

22 Aug, 2024

Offer

13 Sep, 2024

Look Ahead

Lock Up Expiry

13 Mar, 2025

Earning

Nov 1, 2018

IPO Terms

Offer Price $18.00
Offer Size 17M

Market Sentiments

Stock Price